Centered on diabetes, Eli Lilly inks integration offers with Roche, Dexcom, Glooko and extra

The pharmaceutical company Eli Lilly has signed a series of contracts with four diabetes management companies to integrate them into the upcoming Tempo Pen and Tempo Smart Button products.

The companies that have signed strategic international agreements with Eli Lilly are Dexcom, Glooko, myDiabby Healthcare and Roche.

The agreements will integrate Eli Lilly’s Tempo Pen and the associated Tempo Smart Button with the software platforms and / or medical devices offered by the diabetes management companies to enable the collection and sharing of personal health data.

“We are excited to partner with these innovative partners who share our commitment to improving diabetes outcomes by bringing together medications and digital solutions for the global diabetes community,” said Marie Schiller, vice president of product development, Connected Care and Insulins at Eli Lilly. said in a statement.

The Tempo Pen is a modified version of Eli Lilly’s existing pre-filled, disposable insulin pen that attaches to the Tempo Smart Button. The company hopes to receive a CE mark for the smart button later this year and, according to the announcement, will release both products “in several international markets” after certification.

WHY THAT IS

More than 34 million people in the United States have diabetes, according to the CDC.

Diabetes can be controlled with proper treatment, but without it, the disease can lead to hospitalizations, kidney disease, and death. According to the CDC, diabetes was the seventh leading cause of death in the United States in 2017.

These deals will allow future users of the Eli Lilly Tempo line of products to connect to some of the leading platforms and devices in the field of diabetes management, including Dexcom’s Continuous Glucose Monitoring (CGM) devices, Glooko’s digital platform and France’s Diabetes Management -Platform from MyDiabby Healthcare and Roches mySugr App.

“Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses,” said Schiller.

“By integrating data from the connected insulin pen solutions into widely used compatible software, including potential future collaborations, we aim to improve decision-making for people with diabetes and their healthcare providers through accurate, real-time data collection. These solutions can also help remove psychological barriers, such as the fear of hypoglycemia, that can negatively affect diabetes management. “

THE BIGGER TREND

For Roche, this contract follows the contract with Novo Nordisk to connect the mySugr logbook to the NovoPen 6 and NovoPen Echo Plus. At the beginning of the year, the company again agreed to integrate Roche’s Accu-Chek Insights insulin pump into the Diabeloop monitoring system.

Glooko closed a $ 30 million Series D funding round earlier this year to advance the rollout of its remote monitoring platform, expand the commercialization of its products in clinical research, and open up new therapeutic areas.

Dexcom started the year with the introduction of an investment arm called Dexcom Ventures. More recently, the financial results for the first quarter of 2021 were released. Despite a 25% increase in global sales, Dexcom stock has since fallen and is now selling for $ 351, compared to $ 425 in late April.